| Methods |
Crossover design; phase length unclear ‐ could be 8 weeks. 5/21 patients withdrew from study. Said to be double blind (vs placebo), but no other details. Concurrent medication: not stated. |
| Participants |
Inclusion criteria: patients had asthma ‐ diagnosis reasons not stated. Patient details: 16 remaining participants (M/F 9/7); mean age 56; mild asthma; no information about atopy or concurrent COPD. |
| Interventions |
2 interventions: oxitropium bromide 200µg and placebo; both interventions t.i.d. (not stated when). |
| Outcomes |
PEF (am and pm, probably at end of period); FEV1 at end of period. |
| Notes |
Abstract; funded by Boehringer Ingelheim. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
Information not available (Cochrane Grade B) |
